Prophylactic cranial irradiation improved the overall survival of patients with surgically resected

来源 :第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 | 被引量 : 0次 | 上传用户:jerrykfczz
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective: We conducted a retrospective study to evaluate the role of prophylactic cranial irradiation (PCI) on patients with surgically resected small cell lung cancer(SCLC).Method: The records of completely resectable patients who were diagnosed with SCLC and definited TNM stage on the basis of histological studies between January 2003 and December 2009 were reviewed.According to the therapy modality including PCI or not, patients were allocated in PCI group and non-PCI group.
其他文献
Morusin is a prenylated flavonoid that was firstly isolated from the root bark of Morus alba L., possesses anti-HIV, anti-oxidant, anti-inflammatory and anti-tumor activities.
Background: Filamentous microorganisms such as filamentous fungi and bacteria are represented as one of the major sources for bioactive compounds, especially for lead identification in medical science
Semen-derived enhancer of viral infection(SEVI), made up of residues 248-286 of prostatic acidic phosphatase (PAP248-286), is composed of amyloid fibrils that can greatly enhance HIV-1 infectivity and
Influenza virus remains to pose a direct threat to human beings and society for causing severe epidemics of respiratory illness, and highlights an urgent need for new anti-influenza drugs.
Although the current combined anti-retroviral therapy (cART) could successfully control HIV viraemia in infected patients under the detectable level, it fails to completely eradicate the pathogen.
目的:目前尚无低剂量131I用于治疗低刺激性Tg、不伴有远处转移的高危分化型甲状腺癌的相关研究,本研究旨在探讨低剂量131I在这部分人群中的清甲效果.方法:纳入本回顾性研究的标准为:1)年龄>18岁;2)分化型甲状腺癌全切术后;3)T4分期(术中肉眼可见甲外侵犯),任何N分期;4)清甲治疗前刺激性Tg≤5ng/ml;5)无远处转移的证据;6)TgAb≤46IU/ml.这部分患者在TSH刺激状态下(
会议
Objective: AZD9291 is an oral, potent, irreversible EGFR-TKI, selective for sensitizing (EGFRm+) and T790M resistance mutations, currently under investigation in an ongoing Phase Ⅰ study of pts with E
会议
Objective: Dacomitinib (D) is an irreversible pan-HER kinase inhibitor.The ARCHER 1009 global phase Ⅲ study compared D and erlotinib (E) as treatment for locally advanced/metastatic non-small cell lun
会议
Objective: To explore the clinical value and biological characteristics of circulating tumor cells (CTCs) in pulmonary vein (CTCs-pv) from patients with surgically resected non-small cell lung cancer
会议
Objective:This Phase Ⅰ study evaluated the safety, tolerability, and clinical activity ofpembro, a selective anti-PD-1 antibody that blocks the interaction between programmed death-1 (PD-1) on T-cells
会议